A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery

Thrombosis and Haemostasis

Volumn 104, Issue 6, 2010, Pages 1150-1157

  Weitz, Jeffrey I ^a   Cao, Charlie ^b   Eriksson, Bengt I ^c   Fisher, William ^d   Kupfer, Stuart ^b   Raskob, Gary ^e   Spaeder, Jeffrey ^b   Turpie, Alexander G G ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b TAKEDA PHARMACEUTICALS   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Oral factor Xa inhibitor; Thromboprophylaxis; Total knee replacement; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; TAK 442; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTIVE SURGERY; FEMALE; FEVER; HUMAN; HYPOTENSION; INSOMNIA; LIMB PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHLEBOGRAPHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TOTAL KNEE REPLACEMENT; URINE RETENTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHLEBOGRAPHY; PULMONARY EMBOLISM; PYRIMIDINONES; RISK ASSESSMENT; RISK FACTORS; SULFONES; SURGICAL PROCEDURES, ELECTIVE; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 78649720309     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-05-0273     Document Type: Article

References (11)

1. th edition). Chest 2008; 133 (6 Suppl): 381S-453S.
2. Cordell-Smith JA, Williams SC, Harper WM, et al. Lower limb arthroplasty complicated by deep venous thrombosis: prevalence and subjective outcome. J Bone Joint Surg Br 2004; 86: 99-101.
3. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
4. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
5. Turpie AG, Fisher WD, Bauer KA, et al. Bay 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-2486.
6. Weitz J. New oral anticoagulants in development. Thromb Haemost 2010; 103: 62-70.
7. Kawamura M, Konishi N, Hiroe K, et al. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol 2010; doi: 10.1097/FJC.0b013e3181e2bfcf.
8. Konishi N, Hiroe K, Shinozawa E, et al. Antithrombotic profiles of TAK-442, a novel oral factor Xa inhibitor, in venous and arterial thrombosis models. J Thromb Haemost 2009; 7 (Suppl 2): PP-WE-400.
9. Stringer F, Scott G, Kupfer S, et al. The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects. Brit J Clin Pharmacol 2010; in press.
10. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
11. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-2221.